Soluble Expression and Purification of the Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor 2 in Escherichia coli |
Wei, Jia
(State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology)
Cao, Xiaodan (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) Zhou, Shengmin (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) Chen, Chao (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) Yu, Haijun (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) Zhou, Yao (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) Wang, Ping (State Key Laboratory of Bioreactor Engineering, Biomedical Nanotechnology Center, Shanghai Institute of Biomanufacturing Technology, School of Biotechnology, East China University of Science and Technology) |
1 | Wang Y, Xuan Y, Zhang P, Jiang X, Ni Z, Tong L, et al. 2009. Targeting expression of the catalytic domain of the kinase insert domain receptor (KDR) in the peroxisomes of Pichia pastoris. FEMS Yeast Res. 9: 732-741. DOI |
2 | Widmann M, Christen P. 2000. Comparison of folding rates of homologous prokaryotic and eukaryotic proteins. J. Biol. Chem. 275: 18619-18622. DOI |
3 | Wilhelm SM, Carter C, Tang LY, Wilkie D, McNabola A, Rong H, et al. 2004. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64: 7099-7109. DOI |
4 | Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, et al. 2000. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factorinduced responses and tumor growth after oral administration. Cancer Res. 60: 2178-2189. |
5 | Zhao G, Peery RB, Yingling JM. 2007. Characterization and development of a peptide substrate-based phosphate transfer assay for the human vascular endothelial growth factor receptor-2 tyrosine kinase. Anal. Biochem. 360: 196-206. DOI |
6 | Zhong L, Guo XN, Zhang XH, Wu ZX, Luo XM, Jiang HL, et al. 2005. Expression and purification of the catalytic domain of human vascular endothelial growth factor receptor 2 for inhibitor screening. Biochem. Biophys. Acta 1722: 254-261. DOI |
7 | Parast CV, Mroczkowski B, Pinko C, Misialek S, Khambatta G, Appelt K. 1998. Characterization and kinetic mechanism of catalytic domain of human vascular endothelial growth factor receptor-2 tyrosine kinase (VEGFR2 TK), a key enzyme in angiogenesis. Biochemistry 37: 16788-16801. DOI |
8 | Liu C, Guo L, Yao C, Zhang R, Li Y. 2008. Expression and purification of human vascular endothelial growth factor receptor 2 tyrosine kinase in Streptomyces for inhibitor screening. Biotechnol. Appl. Biochem. 50: 113-119. DOI |
9 | O'Farrell AM, Abrams TJ, Yuen HA, Nagi TJ, Louie SG, Yee KW, et al. 2003. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101: 3597-3605. DOI |
10 | Rabhi-Essafi I, Sadok A, Khalaf N, Fathallah DM. 2007. A strategy for high-level expression of soluble and functional human interferon α as a GST-fusion protein in E. coli. Protein Eng. Des. Sel. 20: 201-209. DOI |
11 | Sakurai Y, Ohgimoto K, Kataoka Y, Yoshida N, Shibuya M. 2005. Essential role of Flk-1 (VEGF receptor 2) tyrosine residue 1173 in vasculogenesis in mice. Proc. Natl. Acad. Sci. USA 102: 1076-1081. DOI |
12 | Sambrook JR, Russell DW. 2001. Molecular Cloning: A Laboratory Manual, 3rd Ed. Cold Spring Harbor Laboratory Press, New York. |
13 | Tugues S, Koch S, Gualandi L, Li X, Claesson-Welsh L. 2011. Vascular endothelial growth factors and receptors: anti-angiogenic therapy in the treatment of cancer. Mol. Aspects. Med. 32: 88-111. DOI |
14 | Carvalho JÉF, Blank M, Shoenfeld Y. 2007. Vascular endothelial growth factor (VEGF) in autoimmune diseases. J. Clin. Immunol. 27: 246-256. DOI |
15 | Veeravagu A, Hsu AR, Cai W, Hou LC, Tse VC, Chen X. 2007. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as antiangiogenic agents in cancer therapy. Recent. Pat. Anticancer Drug Discov. 2: 59-71. DOI |
16 | Dyson MR, Shadbolt SP, Vincent KJ, Perera RL, McCafferty J. 2004. Production of soluble mammalian proteins in Escherichia coli: identification of protein features that correlate with successful expression. BMC. Biotechnol. 4: 32. DOI |
17 | Brignola PS, Lackey K, Kadwell SH, Hoffman C, Horne E, Carter HL, et al. 2002. Comparison of the biochemical and kinetic properties of the type 1 receptor tyrosine kinase intracellular domains. Demonstration of differential sensitivity to kinase inhibitors. J. Biol. Chem. 277: 1576-1585. DOI |
18 | Doughervermazen M, Hulmes JD, Bohlen P, Terman BI. 1994. Biological activity and phosphorylation sites of the bacterially expressed cytosolic domain of the KDR VEGF-receptor. Biochem. Biophys. Res. Commun. 205: 728-738. DOI |
19 | Ferrara N. 2001. Role of vascular endothelial growth factor in regulation of physiological angiogenesis. Am. J. Physiol. Cell Physiol. 280: C1358-C1366. DOI |
20 | Ferrara N, Gerber HP, LeCouter J. 2003. The biology of VEGF and its receptors. Nat. Med. 9: 669-676. DOI |
21 | Guo XN, Zhong L, Zhang XH, Zhao WM, Zhang XW, Lin LP, Ding J. 2004. Evaluation of active recombinant catalytic domain of human ErbB-2 tyrosine kinase, and suppression of activity by a naturally derived inhibitor, ZH-4B. Biochem. Biophys. Acta 1673: 186-193. DOI |
22 | Baneyx F. 1999. Recombinant protein expression in Escherichia coli. Curr. Opin. Biotechnol. 10: 411-421. DOI |
23 | Hammarström M, Hellgren N, van den Berg S, Berglund H, Härd T. 2002. Rapid screening for improved solubility of small human proteins produced as fusion proteins in Escherichia coli. Protein Sci. 11: 313-321. DOI |
24 | Arora A, Scholar EM. 2005. Role of tyrosine kinase inhibitors in cancer therapy. J. Pharmacol. Exp. Ther. 315: 971-979. DOI |
![]() |